josko bobanovicJosko Bobanovic
Joško Bobanović joined Sofinnova in 2010 as Partner dedicated to activities in renewable chemistry and industrial biotech. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital and its fund MSBi Capital in Montreal, Canada. Joško was responsible for cleantech investments at the fund, and focused on seed and early stage investments in cleantech and information technology. Prior to his venture capital career he created an internet startup and a software company. After completing his PhD studies Joško developed real-time ocean forecasting systems still used at Environment Canada for coastal ocean management. Joško holds a BSc. in physics from University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.

pawel bochniarzPaweł Bochniarz
• Serial entrepreneur, adviser, mentor and expert in commercialization of new technologies
• Alumnus of Economics studies at the Warsaw University and postgraduate studies - Advanced Management Program on IESE Business School. Expert and adviser experienced within the field of startups creation and acceleration.
• Board chairman of MIT Enterprise Forum Poland and coordinator of Acceleration Program for technological projects realized by this organization
• Previously, i.a. Innovation Advisory Director at PwC, co-founder of Coalition For Polish Innovations

John BorgJohn J Borg
Pharmacist, specialised in Pharmacology currently serves as a Director at the Maltese Medicines Agency (ADM) and is responsible for EU centralised medicinal product evaluations; scientific advice and clinical trials at the Maltese Medicines Agency. Prof. Borg’s professional trajectory has touched several areas of expertise from pre-clinical study to clinical activity as well as R&D of Ion Channel modulators, along with his commitment to teaching and regulatory activity, such as: national and international regulatory activities for the European union; preparation, evaluation and coordination of Research Projects; participation in international bodies etc. Maltese member of the Committee for Human Medicinal Products (CHMP); member of the Committee on Advanced therapies (CAT); member of the Pharmacovigilance Risk Assessment Committee (PRAC); Member of the Paediatric Committee (PDCO); Co-Chair of the European Union Pharmacovigilance Oversight Group and member of the biologics working party (BWP) at the European Medicines Agency. John J Borg trained at the University of Bristol and has published numerous scientific publications as well as chapters in books.

marek borzestowskiMarek Borzestowski
Marek Borzestowski is a CEO of NanoGroup, a holding of biotechnology companies. He is an entrepreneur, manager and founder of numerous innovative companies with over 20 years of experience as a co-owner and board member in leading Polish biotech, IT, and e-commerce companies. After over a decade working as a CEO of a first internet portal in Poland – Wirtualna Polska, he established Polish Israeli VC Giza Polish Ventures. He is a founder of a think tank Sobieski Institute, Startup Hub Poland Foundation. He is a supervisory board member in numerus innovative companies. Marek graduated from the Faculty of Management and Economics at the Gdańsk University of Technology, he also studied at the University of Wales in Great Britain. He conducted a scientific research at the Nuclear Research Center in Karlsruhe and Technical University of Gdansk.

artur chabowskiArtur Chabowski
He is a specialist with over 20 years of experience in the field of international investment banking.
His career started in the Ministry of Ownership Transformations, later he worked i.a. at CAIB Financial Advisers, KPMG, ABN AMRO Corporate Finance and ACADIA. Mr Artur Chabowski is a graduate of the Faculty of Organisation and Management at the Warsaw University of Technology, moreover,
he completed post-graduate studies at the University of Princeton in the Woodrow Wilson School
of Public & International Affairs. He has been associated with Mabion and the life science industry since 2009.

Steffen HeegerSteffen Heeger
Dr. Steffen Heeger joined Selvita in February 2018 and is responsible for all clinical , medical affairs and regulatory functions for Selvita oncology pipeline. Dr. Steffen Heeger is an oncologist with a thorough experience in oncology drug development. Prior to joining Selvita, Dr. Heeger held a position of Vice President, Head of Clinical Development and Head of Clinical Operations at Morphosys AG, where he focused on the development and execution of clinical strategy for Morphosys’ lead hematology and oncology products. Dr. Heeger’s previous experience includes also nine-year tenure at Merck Serono, where he was Head of Medical Affairs and led the Global Clinical Development Team for Erbitux®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Department of Hematology and Oncology of the University Hospital in Heidelberg. Simultaneously with his medical training as a Physician, he also held the position of a Scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

kevin johnsonKevin Jonson
Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently chairman of Levicept Ltd., Apcintex and Crescendo Biologics as well as being a board member of several other startups.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD from Cambridge University.

roland kozlowski fotRoland Kozłowski
Roland received a first class hon¬ours degree from the University of Bath and a PhD from the University of Cambridge. He is a serial bio-entrepreneur, investor and mentor who has worked in the industry for over twenty five years. Roland was Chief Executive Officer of Lec-tus Therapeutics and Sense Proteomic Limited two venture capital backed companies which he founded, built and sold. During his career Roland has lead or played a key role in a many transactions including company financing, sale, purchase, financing and in- and out-licensing with a cumulative value of over $200m. Earlier in his career Roland ran Research Groups at the University of Oxford and University of Bristol where he published and patented in the life science field. He has been a Visiting Industrial Professor, served on, or advised the boards of several European companies and organizations including the Bio-Industry Association in the UK. Presently he is President and owner of Life Science Biznes Consulting which specializes in commercializing technology from emerging economies particularly in Poland. He has acted as an advisor to the National Centre of Research & Development in Poland and the Polish Development Agency. He is a founder and limited partner in Life Science Innovations a specialist VC fund based in Poland and a director or mentor to a number of start-up companies.

robert moldachRobert Mołdach
Robert Mołdach, PhD (Eng), industry expert specializing in health care organization, organizational culture and business development strategies. Acquired management expertise from health care, telecommunications, IT, banking and finance sectors. Educator and promoter of dialogue. Partner and Chairman of the Board at the Institute for Health and Democracy, an advisory and analytical group promoting democratic dialogue on health, based on facts, arguments and scientific evidence.

edwin mosesEdwin Moses
Serial entrepreneur and value creator in European life science companies. As CEO built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing. Was responsible for developing the business plans and implementing them. Ran the sales process for Oxford Asymmetry generating £316M in value. With Ablynx he has secured a bid from Sanofi for the company of €3.9Bn – the transaction is expected to complete in the summer of 2018. Expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. Primarily focussed on high growth businesses and change management. 25 years of Board level experience in more than 10 companies, mostly as Chairman.

kreske nickelsenKreske Nickelsen
Ms Nickelsen is a venture capital professional with more than 18 years of supervisory board and investment experience in companies based all over Europe. Before JPIF, Ms Nickelsen was a partner at Aescap, a life science venture capital fund based in Amsterdam (www.Aescap.com), and before that a director at 3i Group plc in London (www.3igroup.com). She holds an MBA from INSEAD (France) and a Masters in Biology from Philipps University Marburg (Germany).

Łukasz PartykaŁukasz Partyka
CEO & co-founder of KCRI – medical device oriented contract research organization. Lukasz is a vascular medicine physician and experienced project manager. And KCRI supports medical device manufacturers in bringing their innovation safely to market through well designed and executed clinical research programs. Except for market authorization studies KCRI screens and implements medical devices for possible use in clinical trial methodologies (remote sensors, decision support systems, remote consultations, etc.). Established in 2004, KCRI was instrumental in First-In-Human applications of complicated and invasive devices and also supported largest players on the market in their late, post-marketing strategies.

marcin szumowskiMarcin Szumowski
Marcin Szumowski is serial entrepreneur. He received his MS and PhD degrees from the University of Illinois and earned an MBA degree in entrepreneurship and international finance. Following a successful research career in the United States, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed five start-ups, including a medical diagnostics company Medicalgorithmics S.A. (www.medicalgorithmics.com), where he was President and CEO 2005-2011. Medicalgorithmics is present on 5 continents, has been listed on the Warsaw Stock Exchange and has reached a market cap of over $300M. Since 2013 Marcin is President & CEO of OncoArendi Therapeutics S.A. (www.oncoarendi.com), a Polish innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for neoplastic, inflammatory and fibrotic diseases. In five years the company has grown to over 80 employees and raised over $65M research funding from private investors and public grants. OncoArendi was recently listed on the Warsaw Stock Exchange with IPO valuation of approx. $120 million. The company has assets in late phase I and in late preclinical development. Marcin is also one of co-founders and lead investors of the Life Science Innovations (LSI) seed fund. Since 2012 Marcin has assisted the European Commission on three independent expert panels performing the impact assessment, interim and final evaluations of the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership (PPP) in pharmaceutical research. Over the last 20 years Marcin has managed over 50 R&D and investment projects with a total value well over $300M.

heiko visarius fotHeiko Visarius
Dr. Heiko Visarius is an executive with international experience in the health care sector, especially in the area of medical device technology. A Ph.D. in engineering obtained in the USA and a Swiss/US MBA degree combined with his professional experience allow him to relate to a broad spectrum of business areas, such as sales, marketing, R&D, finance, supply chain and general management. Dr. Heiko Visarius served as CEO of a successful start-up company with an associated exit. Since then, he held various leadership positions with global players of the medical device industry (Synthes/J&J, Medtronic). He had P/L responsibility in Europe for a 3-digit million USD revenue volume in a direct operation. Since 2012, he is owner of VISARTIS Healthcare GmbH. In addition, Dr. Visarius is board member of several Medtech companies as well as an international business school and serves on various expert boards, including Horizon2020 (European Community). He and his family are located in Switzerland.

Simon WallworkSimon Wallwork
Simon Wallwork is a partner of Slater Heelis, Solicitors, based in Manchester, UK.and leads its Corporate Team. With over 30 years experience advising on acquisitions, disposals, private equity and public market transactions, for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships, Simon also has considerable client side experience spending a number of years working in-house with Pilkington plc. Simon’s practice covers both UK and International clients and he regularly advises on cross border transactions. He has advised clients on listings on stock markets in the UK, USA, Poland, Belgium, Germany, Hong Kong and Australia. Simon is recognised as one of the leading corporate lawyers in the North West of England. Simon has worked in the life sciences sector for over 20 years. He has a deep understanding of the sector and its key drivers. He has acted for over 35 companies in development capital deals over the last 2 years. He is a member of the Strategic Advisory Board of BIONOW, the cluster organisation for the Biotech Sector in the North of England and a Gold Partner of the Daresbury Campus in Warrington, England, an incubator for Life Sciences and Tech companies. He has also given strategic advice to Manchester University, Liverpool University and Alder Hay Childrens Hospital on their commercialisation strategies.

Paweł WielgusPaweł Wielgus
MSc Eng. in biotechnology (Wroclaw University of Technology, 2004), financial analyst (Wroclaw University of Economy, 2009), PhD in chemistry (Wroclaw University of Technology, 2010). Participant of the International Max Planck Research School, a prestigious international PhD program (2005-2008). Beneficiary of a research grant awarded by the Committee for Scientific Research (2009-2010). Scientific consultant and trainee at the Jackson State University, Mississippi, USA (2004, 2005) and the Max Planck Institute for Solid State Physics, Dresden, Germany (2005-2007). Participant of numerous conferences, workshops and symposia organized among others by the Universities of Palermo, Valencia , Helsinki and Geneva. Author and co-author of several scientific papers published in leading international journals. In the past professionally linked to Wroclaw Research Centre EIT+ Ltd., initially as Business Coach (3.1 Operational Program Innovative Economy VC fund, 2010), then as Key Account Manager in Life Sciences Dept. (2011-2012) and finally as Deputy Director of Business Development Department for Commercialization and Intellectual Property Management (in charge of 3.1 Operational Program Innovative Economy VC fund; responsible for corporate governance and commercialization of results of scientific research carried out in Biotechnology and Nanotechnology Depts., 2013). Chairman of the Audit Committee in the Association of Individual Investors, the largest organization of private investors in the CEE region (since Oct. 2011). In the past also an employee in the Association of Individual Investors, initially as a specialist in Legal Dept. and then as Director for Legal Dept. (2008-2010). Member of supervisory boards of companies listed on the Warsaw Stock Exchange: Lentex SA (2009-2011) and Plastics Processing Plast-Box SA (2011-2012). Chairman of the Board in Lentex ChemFund Management Ltd. (2010-2011). The co-founder and a Member of the Board of Startit Fund Sp. z o.o. [Ltd.], a transfer-of-technology centre and investment fund rolled into one, and Kvarko ASI sp. z o.o [Ltd.], a fund created within Bridge Alfa Programme (1.4 Smart Growth Operational Programme 2014-2020). Former member of supervisory boards of several start-up companies (Simply User, Nanovectors, InnovaLab, Incuvo, Lipid Systems). Qualified for the Top500 Innovators program organized under the auspices of the Ministry of Science and Higher Education (2012). Lecturer at the Higher School of Banking in Wroclaw ("Models of commercialization of the intellectual property", 2012) as well as at the International School of Logistics and Transport in Wroclaw ("Commercialization as a path to success", 2012). Experience supported by in-depth analyses of over one hundred of scientific research projects and successful transactions of investments and exits concerning start-up companies. Certified Adviser in the alternative trading system New Connect in Warsaw (since 2012).